TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$17.26
+1.17%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 9.65x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 7.65x
- Price / sales
- —
- Price / cash flow
- -46.73x
Enterprise value
- Enterprise value
- $2.1B
- EV / sales
- —
- EV / EBITDA
- -41.92x
- EV / EBIT
- -35.95x
- Market cap
- $2.5B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026